about
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are goingFollow-up of patients with early breast cancer: is it time to rewrite the story?Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialReproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.Fertility issues in young breast cancer patients: what women want.Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study.Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitorsSentinel lymph node biopsy in breast cancer patients: the medical oncology perspective.Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.Infertility and pregnancy after breast cancer: current knowledge and future perspectives.Safety of adjuvant aromatase inhibitor therapy.Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.Fertility counseling of young breast cancer patients.Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives.Medical approaches to preservation of fertility in female cancer patients.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.Gene expression profiling in breast cancer: a clinical perspective.The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs).Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.Targeting bone metastatic cancer: Role of the mTOR pathway.Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.Exploring the safety of chemotherapy for treating breast cancer during pregnancy.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.News on the medical treatment of young women with early-stage HER2-negative breast cancer.
P50
Q26750740-3EEE29DC-5CF0-4DFA-A00D-3985B514A469Q27001525-E9618730-9EFF-4329-AB5C-E765798C583CQ28288726-854C6524-964B-42AA-950C-AC00F65F064EQ30248475-96118135-A407-404B-80A5-57B7C4B555EBQ33369478-E5D3BE9F-9D44-433B-9C4C-B5C99E5D9FA4Q33496962-5E7D3919-7E23-4759-975B-AA7053D3359EQ33814713-CBDA7764-E86C-4059-BD82-6C9E97520C04Q34294414-135BA942-AEE1-4FFA-B2B7-8956A5BFC795Q34393606-3121B40F-B725-4EF1-AADB-E00AD436C1A8Q34640591-BF555D24-EE15-4F16-A5FD-A1B2CDE9463CQ35460114-42D89F50-CAC6-4C13-94D0-336EFC3301DEQ35583869-6E26F34B-65B1-4F97-93EA-13DF85183CA7Q35678617-857F5120-679E-4C63-92E6-C13FD1A04CB4Q35766397-6DB25203-EEF6-43B2-BE93-8403E6EA7622Q35915735-199D89EF-A361-44C3-8A80-416DDA09259BQ36139709-04951F93-EAB3-4357-8ECF-BA3FFA8B3BBFQ36478763-4A6D6EA1-9ABC-46CC-9ED1-7DB4DD4B3A10Q36484937-E7CA7397-9D6E-4339-8EA5-C07F6F32B032Q36536914-54CE21CE-9824-4905-A21D-B869BA8C2981Q36606491-DA8E89E0-ED60-46A4-B1DE-394537681F5EQ36762909-F59C841A-987F-4DE0-A75F-6D4E2F8D21D4Q36938850-6032BD21-236C-4B61-A7B9-DB1248A32299Q36963384-E3FED351-F837-45F3-9FA7-B6EDA8DB8A45Q37632155-F18FE410-CF02-4F9F-913D-7760C70212CBQ37781184-304B825D-E2B0-4079-B323-9A0DEE36D310Q37831349-14E58190-C643-43C0-BCE6-EB7F4F0F6BF6Q37931905-15F9CD4A-3D54-4B8E-87C8-FA33B1AB8B3AQ38052616-78D9811B-A4A6-479D-B531-50807A2498F0Q38086710-4ED5C573-B5AD-451A-949A-4ADD7EFD05DDQ38138232-C27A7A6D-481F-4D33-8F18-9A193950A48FQ38167624-F928C917-6D9F-4E70-9522-D8346BA0E8F8Q38186452-0AD4781F-B610-4A4D-B7A8-E73D1300061EQ38397868-A40BC73B-53BB-4309-83A4-C0F227696050Q38487646-F4B8CCB4-99B8-424B-9711-42B635813D31Q38539265-5B22C2FD-43AD-4630-BDE3-CBA886FF2223Q38613025-88CD4CBA-04CE-4A84-AC07-4F2906EE0DB3Q38648577-25EB1155-D985-46F3-B974-8A0B6402F668Q38650494-2388E221-37F4-4A08-8C7A-1F11077F3272Q38658655-31B55F56-C843-4AC2-AA1B-E73094FEA5EDQ38870541-76552428-3454-4E65-A6AB-EC2EE173AB27
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lucia Del Mastro
@ast
Lucia Del Mastro
@en
Lucia Del Mastro
@es
Lucia Del Mastro
@sl
type
label
Lucia Del Mastro
@ast
Lucia Del Mastro
@en
Lucia Del Mastro
@es
Lucia Del Mastro
@sl
prefLabel
Lucia Del Mastro
@ast
Lucia Del Mastro
@en
Lucia Del Mastro
@es
Lucia Del Mastro
@sl
P1053
J-6163-2016
P106
P1153
7004319367
P21
P31
P3829
P496
0000-0002-9546-5841